Nancy U. Lin

Also affiliated with Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.8Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Nature Cancer(2022)10.1038/s43018-022-00491-x

Top 9%

2.4DataRank

Top 9%114 citations

Toshinori Hinoue, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro, Tomás Pascual +53 more

Papers

Driven by 71 papers — median percentile 88. Top paper: “Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer”.

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3958

N/A

4.2DataRank · unranked

185 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +15 more

Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions

Neuro-Oncology(2022)10.1093/neuonc/noac118

N/A

3.5DataRank · unranked

197 citations

Nayan Lamba, Manmeet S. Ahluwalia, Kenneth Aldape, Adrienne Boire, Priscilla K. Brastianos +20 more

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast Cancer Research(2020)10.1186/s13058-020-01354-y

N/A

3.0DataRank · unranked

148 citations

Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo +18 more

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Nature Cancer(2022)10.1038/s43018-022-00491-x

Top 9%

2.4DataRank

Top 9%114 citations

Toshinori Hinoue, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro, Tomás Pascual +53 more

Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival

Neuro-Oncology(2020)10.1093/neuonc/noaa025

N/A

2.3DataRank · unranked

77 citations

Shane Mesko, Jing Li, Daniel Cagney, Ayal A. Aizer, Nancy U. Lin +34 more

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer

Journal of Neuro-Oncology(2020)10.1007/s11060-020-03555-z

N/A

1.9DataRank · unranked

82 citations

Martin Fleisher, Priya Kumthekar, Xuling Lin, Antonio Omuro, Morris D. Groves +12 more

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

Nature Communications(2021)10.1038/s41467-021-25769-z

N/A

1.8DataRank · unranked

48 citations

Jennifer L. Guerriero, Romualdo Barroso‐Sousa, Tianyu Li, Tess A. O’Meara, Anita Giobbie‐Hurder +24 more

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

Nature Medicine(2023)10.1038/s41591-023-02392-7

N/A

1.6DataRank · unranked

66 citations

Albert E. Kim, Anita Giobbie‐Hurder, Eudocia Q. Lee, Nancy U. Lin, Beth Overmoyer +28 more

A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features

Nature Medicine(2024)10.1038/s41591-024-03215-z

Top 15%

1.3DataRank

Top 15%91 citations

Daniel L. Abravanel, Åsa Segerstolpe, Timothy R. Blosser, Yury Goltsev, Yi Cui +57 more

A pathology foundation model for cancer diagnosis and prognosis prediction

Nature(2024)10.1038/s41586-024-07894-z

N/A

0.927DataRank · unranked

482 citations

Junhan Zhao, Eliana Marostica, Wei Yuan, Jietian Jin, Jiayu Zhang +24 more

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0215

N/A

0.854DataRank · unranked

295 citations

Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai +44 more

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

Nature Communications(2022)10.1038/s41467-022-30568-1

N/A

0.832DataRank · unranked

255 citations

Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar Kabraji, Melissa E. Hughes +14 more

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update

Journal of Clinical Oncology(2022)10.1200/jco.22.00519

N/A

0.778DataRank · unranked

178 citations

Maria Alice Franzoi, Sarah Temin, Carey K. Anders, Sarat Chandarlapaty, Jennie R. Crews +9 more

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.02.008

N/A

0.759DataRank · unranked

157 citations

Ofir Cohen, Bose Kochupurakkal, D. Kim, Connor E. Dunn, Jorge Buendia +20 more

Liquid biopsy epigenomic profiling for cancer subtyping

Nature Medicine(2023)10.1038/s41591-023-02605-z

N/A

0.722DataRank · unranked

122 citations

Ji-Heui Seo, Matthew P. Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian +38 more

Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

Nature Reviews Clinical Oncology(2023)10.1038/s41571-023-00756-z

N/A

0.683DataRank · unranked

94 citations

Rupert Bartsch, Émilie Le Rhun, Anna S. Berghoff, Priscilla K. Brastianos, Javier Cortés +8 more

Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer

Therapeutic Advances in Medical Oncology(2022)10.1177/17588359221113269

N/A

0.672DataRank · unranked

15 citations

Jennifer L. Guerriero, Sergey Naumenko, Shom Goel, Meredith M. Regan, Jiani Hu +10 more

A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics

Neuro-Oncology(2022)10.1093/neuonc/noac195

N/A

0.663DataRank · unranked

82 citations

Michael J. Avram, Andrew B. Lassman, Nancy U. Lin, Eudocia Q. Lee, Sean Grimm +13 more

Integrative multiomics-histopathology analysis for breast cancer classification

npj Breast Cancer(2021)10.1038/s41523-021-00357-y

N/A

0.584DataRank · unranked

48 citations

William Yuan, Deborah Dillon, Nancy U. Lin, Jeffrey A. Golden, Isaac S. Kohane +2 more

p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases

Nature Communications(2022)10.1038/s41467-022-29081-2

N/A

0.470DataRank · unranked

22 citations

Sheheryar Kabraji, Shaozhen Xie, Yanzhi Wang, Peichen Pan, Xiaofang He +9 more

Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae314

N/A

0.443DataRank · unranked

10 citations

William E. Barlow, Julie R. Gralow, Funda Meric‐Bernstam, Kathy S. Albain, Daniel F. Hayes +19 more

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

bioRxiv (Cold Spring Harbor Laboratory)(2019)10.1101/605436

N/A

0.425DataRank · unranked

16 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +15 more

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆

ESMO Open(2024)10.1016/j.esmoop.2024.103973

N/A

0.385DataRank · unranked

12 citations

Danielle Brandes Zakon, Qingchun Jin, Ava Strahan, Melissa Grimm, Melissa E. Hughes +15 more

Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients

JNCI: Journal of the National Cancer Institute(2025)10.1093/jnci/djaf048

N/A

0.373DataRank · unranked

11 citations

Thibaut Sanglier, José Pablo Leone, Timothy K Erick, Peter Lambert, Filippo Montemurro +5 more

Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer

npj Breast Cancer(2024)10.1038/s41523-023-00605-3

N/A

0.360DataRank · unranked

10 citations

Jia‐Ren Lin, Ricardo Pastorello, Ziming Du, Yu-An Chen, Madeline G Townsend +17 more

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance

Neuro-Oncology(2023)10.1093/neuonc/noad236

N/A

0.323DataRank · unranked

6 citations

Kevin W Lou, Anita Giobbie‐Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel +38 more

Contrastive learning enhances fairness in pathology artificial intelligence systems

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102527

N/A

0.311DataRank · unranked

6 citations

Pei-Chen Tsai, Fang-Yi Su, Chun-Yen Chen, Fuchen Li, Junhan Zhao +33 more

Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2

ESMO Open(2025)10.1016/j.esmoop.2024.104111

N/A

0.282DataRank · unranked

5 citations

P. Tarantino, Rong Li, Albert Grinshpun, Hersh Gupta, Melissa E. Hughes +12 more

Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer

npj Breast Cancer(2024)10.1038/s41523-024-00647-1

N/A

0.241DataRank · unranked

4 citations

Douglas Russo, Wen Ma, Ana Verma, Francisco Hermida-Prado, Shira Sherman +13 more

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07417-4

N/A

0.215DataRank · unranked

3 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis

Research Square(2022)10.21203/rs.3.rs-1221704/v1

N/A

0.165DataRank · unranked

2 citations

Susana García‐Recio, Toshinori Hinoue4, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro +49 more

Author Correction: A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features

Nature Medicine(2025)10.1038/s41591-025-03665-z

N/A

0.104DataRank · unranked

1 citations

Daniel L. Abravanel, Åsa Segerstolpe, Timothy R. Blosser, Yury Goltsev, Yi Cui +57 more

Genomic profiling of breast cancer brain metastases reveals targetable alterations.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2525

N/A

0.104DataRank · unranked

1 citations

Liam F. Spurr, Melissa E. Hughes, Yvonne Y. Li, José Pablo Leone, Ana C. Garrido-Castro +8 more

Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy

ESMO Open(2025)10.1016/j.esmoop.2025.105568

N/A

0.104DataRank · unranked

1 citations

Qi Jin, Agepati S. Raghavendra, Danielle Brandes Zakon, Melissa Grimm, Melissa E. Hughes +16 more

Humoral immune responses to the second dose of a COVID-19 mRNA vaccine in cancer patients undergoing treatment

Human Vaccines & Immunotherapeutics(2025)10.1080/21645515.2025.2570963

N/A

0.104DataRank · unranked

1 citations

Troy J. Kemp, Nancy Roche, Katarzyna Haynesworth, Sarah Loftus, Benjamin J. Borski +10 more

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial

UNC Libraries(2025)10.17615/dgtt-ap31

N/A

0DataRank · unranked

0 citations

Julie R. Gralow, Edith Perez, Kevin Kalinsky, Gabriel N. Hortobágyi, Nancy U. Lin +19 more

Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2529

N/A

0DataRank · unranked

0 citations

Ken Chang, Andrew Beers, Kyrre E. Emblem, Jayashree Kalpathy–Cramer, Eudocia Q. Lee +15 more

Supplemental Table 12 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476836

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 6 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476818.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 10 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476842

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 5 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476821

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 5 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476821.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 13 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476833.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 8 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476812

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 3 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476827

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 12 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476836.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 10 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476842.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 7 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476815

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 11 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476839.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 7 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476815.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplementary Data from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476806

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 4 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476824

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 3 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476827.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 6 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476818

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 4 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476824.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 13 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476833

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplementary Data from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476806.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 2 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476830.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Supplemental Table 8 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22476812.v1

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today

International Journal of Radiation Oncology*Biology*Physics(2020)10.1016/j.ijrobp.2020.01.051

N/A

0DataRank · unranked

148 citations

Shane Mesko, Jing Li, Daniel Cagney, Ayal A. Aizer, Nancy U. Lin +34 more

Supplemental Table 11 from Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer

(2023)10.1158/1078-0432.22476839

N/A

0DataRank · unranked

0 citations

Ofir Cohen, Kailey J. Kowalski, Justin G. Kusiel, Jorge E. Buendia-Buendia, Michael S. Cuoco +16 more

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

UNC Libraries(2020)10.17615/bgrr-9v25

N/A

0DataRank · unranked

0 citations

Anna Maria Storniolo, Vered Stearns, Vandana G. Abramson, Joel S. Parker, Catherine Van Poznak +19 more

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

UNC Libraries(2020)10.17615/7w8k-g207

N/A

0DataRank · unranked

0 citations

Ann Crawford, Annick D. Van den Abbeele, Rebecca Gelman, Steven E. Come, Xiaochun Li +13 more

A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients With Breast Cancer and Brain Metastases

UNC Libraries(2020)10.17615/arc0-j974

N/A

0DataRank · unranked

0 citations

Lixian Sun, Eric P. Winer, Rachel A. Freedman, Elizabeth Bullitt, Nancy U. Lin +6 more

Blood Vessel Morphologic Changes Depicted with MR Angiography during Treatment of Brain Metastases: A Feasibility Study

UNC Libraries(2020)10.17615/50wc-6m30

N/A

0DataRank · unranked

0 citations

J. Keith Smith, Matthew G. Ewend, Donglin Zeng, Eric P. Winer, Weili Lin +3 more

The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer

The Journal of Clinical Endocrinology & Metabolism(2022)10.1210/clinem/dgac375

N/A

0DataRank · unranked

16 citations

Melissa E. Hughes, Julia C. Harrod, Janet Files, Greg Kirkner, Lauren Buckley +5 more

Adapting and Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care (Project ADAPT): Protocol for an Implementation Science–Based Study

JMIR Research Protocols(2022)10.2196/35736

N/A

0DataRank · unranked

5 citations

Uzoma Charles Okere, Graham A. Colditz, X. Cynthia, Jingxia Liu, Courtney Harriss +9 more

Data from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

(2023)10.1158/1078-0432.c.6532872

N/A

0DataRank · unranked

0 citations

Jing Ni, Sarah Sammons, Tianyu Li, Amanda E.D. Van Swearingen, Yanzhi Wang +14 more

Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.25.554868

N/A

0DataRank · unranked

0 citations

Kevin W Lou, Anita Giobbie‐Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel +38 more

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Research Square(2024)10.21203/rs.3.rs-4295044/v1

N/A

0DataRank · unranked

0 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

Clinical Breast Cancer(2025)10.1016/j.clbc.2025.05.009

N/A

0DataRank · unranked

0 citations

Xiangying Chu, Tarah J. Ballinger, Nisha Unni, Sarah Sinclair, Robert Wesolowski +9 more

Nancy U. Lin

Indexed papers

Top data-sharing exemplar

Papers